Literature DB >> 2296381

The changing patterns of death rates in parkinsonism.

J F Kurtzke1, F M Murphy.   

Abstract

Annual crude death rates due to parkinsonism in Denmark, 1956 to 1985, and the United States, 1950 to 1984, showed a consistent hierarchy, with white male rates greater than white female than black male than black female. Rates rose sharply in both lands and sexes between 1976 and 1984. Age-specific death rate curves for whites in the 1960s and 1980s were very similar between the countries with a regular male excess. Both countries drastically changed the configuration of all the death rate age curves in parallel fashion between the 2 periods: rates were now nearly twice those of the earlier interval for each sex, age, and race, and were then maximal at age 82 or 85+ as opposed to the prior peak at age 77 or 80. Age-adjusted rates did not consistently reflect this change, being markedly lower for US white females despite their age-specific rate increases. This discrepancy appears to be an artifact of changing population distributions which increasingly differ by age between sexes and countries over time. When the recent age-specific death rates were recalculated with the thesis that all deaths had occurred at ages 5 years younger, all the 1980s death rate configurations returned to those of the 1960s, with but modest increases at most ages. This is evidence that age at death, and thus survival, has increased at all ages by about 5 years since the introduction of levodopa, released in the US in 1970 and in Denmark in 1971.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2296381     DOI: 10.1212/wnl.40.1.42

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Validity of mortality data for Parkinson's disease.

Authors:  N J Phillips; J Reay; C N Martyn
Journal:  J Epidemiol Community Health       Date:  1999-09       Impact factor: 3.710

Review 3.  How far are we in understanding the cause of Parkinson's disease?

Authors:  Y Ben-Shlomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

4.  Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991.

Authors:  P A Schulte; C A Burnett; M F Boeniger; J Johnson
Journal:  Am J Public Health       Date:  1996-09       Impact factor: 9.308

5.  Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.

Authors:  H Przuntek; D Welzel; E Blümner; W Danielczyk; H Letzel; H J Kaiser; P H Kraus; P Riederer; D Schwarzmann; H Wolf
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Mortality from Parkinson's disease in England and Wales 1921-89.

Authors:  C E Clarke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

7.  Mortality in levodopa-treated Parkinson's disease.

Authors:  John C Morgan; Lillian J Currie; Madaline B Harrison; James P Bennett; Joel M Trugman; G Frederick Wooten
Journal:  Parkinsons Dis       Date:  2014-01-28

Review 8.  Epidemiology of Parkinson's disease.

Authors:  C M Tanner; S M Goldman
Journal:  Neurol Clin       Date:  1996-05       Impact factor: 3.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.